SPYRE THERAPEUTICS, INC. Cash Equivalents, at Carrying Value
SPYRE THERAPEUTICS, INC. (SYRE) had Cash Equivalents, at Carrying Value of $160.26 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashEquivalentsAtCarryingValue · last filed 2026-08-04
- 2026-06-30: Cash Equivalents, at Carrying Value $160.26M.
- 2026-03-31: Cash Equivalents, at Carrying Value $95.45M.
- 2025-12-31: Cash Equivalents, at Carrying Value $83.99M.
- 2025-09-30: Cash Equivalents, at Carrying Value $63.18M.
| Period end | Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $160.26M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $95.45M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $83.99M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $63.18M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $79.96M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $46.80M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $87.73M 10-K · filed 2026-02-19 |
| 2024-09-30 | $69.90M 10-Q/A · filed 2024-11-18 |
| 2024-06-30 | $43.38M 10-Q/A · filed 2024-11-18 |
| 2024-03-31 | $225.80M 10-Q/A · filed 2024-11-18 |
| 2023-12-31 | $186.56M 10-K · filed 2025-02-27 |
| 2023-09-30 | $72.36M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $18.86M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $32.28M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $26.01M 10-K/A · filed 2024-11-18 |
| 2022-09-30 | $26.02M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $28.48M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $9.80M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $8.89M 10-K · filed 2023-03-02 |
| 2021-09-30 | $16.13M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $21.86M 10-Q · filed 2021-08-05 |
| 2020-12-31 | $77.60M 10-K · filed 2022-03-08 |
| 2020-06-30 | $53.80M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $11.52M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $15.52M 10-K · filed 2021-03-18 |
| 2019-09-30 | $19.70M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $20.19M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $26.84M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $19.41M 10-K · filed 2020-02-24 |
| 2018-09-30 | $12.80M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $19.05M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $7.62M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $8.92M 10-K · filed 2019-03-07 |
| 2017-09-30 | $11.21M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $12.75M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $14.03M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $43.83M 10-K · filed 2018-03-13 |
| 2016-09-30 | $45.54M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $21.25M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $21.05M 10-Q · filed 2016-05-19 |
| 2015-12-31 | $20.24M 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |